AssetID: 56099189
Headline: Experimental mRNA Vaccine Cuts Risk Of Melanoma Returning By 42%
Caption: An experimental personalised mRNA cancer vaccine reduced the risk of melanoma returning after surgery or death by 42% in a late-stage clinical trial.
Keywords: Health & Wellbeing,melanoma,mRNA vaccine,cancer vaccine,intismeran autogene,Moderna,Merck,Keytruda,cancer treatment,cancer research,immunotherapy,clinical trial,oncology,tumour,immune system
PersonInImage: